June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
The Obesity Paradox in Uveal Melanoma: Body Mass Index >30 is associated with lower metastatic risk
Author Affiliations & Notes
  • Shiva Sabazade
    Clinical Neuroscience Eye/Vision, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Adrianna Helena Opalko
    Clinical Neuroscience Eye/Vision, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Viktor Gill
    Clinical Neuroscience Eye/Vision, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Christina Herrspiegel
    Clinical Neuroscience Eye/Vision, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Gustav Stålhammar
    Clinical Neuroscience Eye/Vision, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Footnotes
    Commercial Relationships   Shiva Sabazade None; Adrianna Opalko None; Viktor Gill None; Christina Herrspiegel None; Gustav Stålhammar None
  • Footnotes
    Support  Fru Sandqvist Stiftelse
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2349 – A0018. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shiva Sabazade, Adrianna Helena Opalko, Viktor Gill, Christina Herrspiegel, Gustav Stålhammar; The Obesity Paradox in Uveal Melanoma: Body Mass Index >30 is associated with lower metastatic risk. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2349 – A0018.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To examine the association between metabolic factors and the risk of metastasis in uveal melanoma.

Methods : Data on patient body mass index, cardiovascular diseases, diabetes, use of anticoagulants, antihypertensives, diuretics, statins and hypothyroidism replacement therapy at the time of diagnosis were collected from all patients diagnosed with uveal melanoma at St. Erik Eye Hospital, Stockholm, Sweden from January 2009 through December 2017. The hazard ratio (HR) for metastasis was then calculated with Cox regressions. Obesity was defined as a BMI of 30.0 or above.

Results : Data on the presence of cardiovascular diseases, use of anticoagulants, antihypertensives and hypothyroidism replacement therapy was available for 683 patients. For 581 of these, body mass index (BMI) was available and for another 200, we also had data on the presence of diabetes type 1 and 2 and the use of statins, diuretics, metformin and insulin. A total of 465 patients (80%) were non-obese and a total of 116 patients (20%) were obese. In univariate Cox regression, tumor diameter (HR 1.2 per increasing mm, p<0.0001) and diabetes type 1 or 2 (HR 1.9, p=0.05) were associated with metastasis. Obesity was negatively correlated (HR 0.6, p=0.04). In multivariate Cox regression, tumor diameter (HR 1.2, p<0.0001) and obesity (HR 0.4, p=0.006) retained their significance

Conclusions : Obesity is associated with lower metastatic risk in uveal melanoma, independent of tumor size and diabetes.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Figure 1.
Multivariate Cox regressions. Cumulative hazard ratios (HR) for metastasis by Body Mass Index (BMI) categories, adjusted for tumor diameter.
A. Patients with Body Mass Index (BMI) ≥ 25 versus < 25 (HR 0.7, 95 % CI 0.5 - 1.1 p=0.14).
B. Patients with BMI ≥ 30 versus < 30 (HR 0.4, 95 % CI 0.2 - 0.8, p=0.006).
C. Patients with BMI Class 1 (BMI <18.5), BMI Class 2 (BMI 18.5 - 24.9) BMI Class 3 (BMI 25 - 29.9) and BMI Class 4 (BMI ≥ 30, HR 0.7, 95 % CI 1.1 - 1.2, p=0.008).

Figure 1.
Multivariate Cox regressions. Cumulative hazard ratios (HR) for metastasis by Body Mass Index (BMI) categories, adjusted for tumor diameter.
A. Patients with Body Mass Index (BMI) ≥ 25 versus < 25 (HR 0.7, 95 % CI 0.5 - 1.1 p=0.14).
B. Patients with BMI ≥ 30 versus < 30 (HR 0.4, 95 % CI 0.2 - 0.8, p=0.006).
C. Patients with BMI Class 1 (BMI <18.5), BMI Class 2 (BMI 18.5 - 24.9) BMI Class 3 (BMI 25 - 29.9) and BMI Class 4 (BMI ≥ 30, HR 0.7, 95 % CI 1.1 - 1.2, p=0.008).

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×